Does Low Dose Atropine Really Work??

Listen On

As a pediatric ophthalmologist and mom of three, I spend a lot of time thinking about what we are not telling parents.

Not the information we forget to mention because we're rushed.

The other kind.

The kind you leave out because it feels complicated, or because you assume they won't want to hear it, or because somewhere along the way our entire profession decided that a child's nearsightedness was just a glasses problem and not a health problem.

How many parents are sitting in exam rooms right now watching their child's prescription climb every single year, and nobody has told them it doesn't have to be that way?

How many kids are going to grow into adults with serious, irreversible eye disease because the window to intervene closed while everyone was busy just updating the prescription?

And what does that cost — not just in vision, but in quality of life, in independence, in the version of the future that child deserves?

In this episode of In Focus: Vision, Clarity and Eye Health for the Whole Family, I sat down with one of the people I respect most in pediatric ophthalmology — Dr. Robert Clark, founder of South Bay Family Eye in California, associate clinical professor at UCLA Stein Eye Institute, and someone who has treated over a thousand children with low-dose atropine over the course of his career. He is also the person who first brought me into this conversation, years ago, when we started doing panels together on pediatric myopia management. He knows this science like almost nobody else. And I wanted to get into all of it — why these treatments work, what the research actually says, and what parents need to know right now.

Why This Topic Matters Right Now

There is a particular kind of helplessness that comes from watching something get worse when you didn't know you could have stopped it.

We are in the middle of an explosion in childhood nearsightedness. Over the last two decades, rates have climbed dramatically. And the reason is not mysterious — we have shifted our children from mixed visual activity and outdoor time toward near work and screens and indoor everything. A good education system now almost requires the conditions that are hardest on developing eyes. We are not doing anything wrong, exactly. We just haven't caught up to what that shift means biologically.

The thing most parents don't understand is that nearsightedness is not just a focusing problem. It is a structural one. When a child becomes myopic, their eye is physically growing too long. The retina — the light-sensitive tissue at the back of the eye — stops developing around age three or four. But the eye itself can keep elongating well past that. Dr. Clark described it this way: think about taking the same amount of carpet and spreading it over a bigger and bigger room. Eventually the carpet is going to rupture and tear. That is what happens to the retina under pathological elongation. That is what leads to retinal detachments. To glaucoma. To cataracts. To myopic maculopathy — which is now the leading cause of irreversible vision loss in much of the world.

Vision loss that glasses cannot fix. That laser surgery cannot fix. That cataract surgery cannot fix.

And here is the part that I think about constantly as both a doctor and a mom: whatever eye size a child gains during childhood, they keep for life. You cannot reverse it later. The time to act is while they are still growing.

The Moment That Finally Changed How I Practice

I started using low-dose atropine in 2014. Dr. Clark started even earlier — after the ATOM2 study came out in 2012, and before that with higher concentrations going back decades. When I first heard the science, I felt genuinely angry that this information wasn't more widely known. I had been trained to hand families a new prescription and send them home. Nobody had framed it to me as: this is a disease that progresses, there are interventions that slow it, and you have a window that closes.

The data is striking. Each diopter of myopia that a child accumulates increases their lifetime risk of serious eye disease by roughly 40 percent. That means keeping a child at a minus three instead of a minus four — not glasses-free, just one number lower — translates into meaningfully less disability later in life. Dr. Clark described it as an order of magnitude difference. That is not a rounding error. That is a child's future.

Why We Can't Just Keep Giving Kids Stronger Glasses — It's Not a Neutral Act

Before we talk about what actually works, we need to talk about what standard care is doing.

Standard single-vision glasses and contact lenses correct central vision. But they leave peripheral vision over-focused in a way that actually signals the eye to keep growing. This is not theoretical — it has been demonstrated in animal studies and confirmed in human data. If you give a child a standard lens, you are correcting their vision in the short term while accelerating the underlying problem.

Dr. Clark put it plainly: why would you give a child an optical device that makes their myopia worse, when there are devices available that don't? He compared it to selling someone a car without airbags. You could save a little money. You could also not do that.

The Three Interventions That Actually Work

The good news — and I want to be clear that there is genuinely good news here — is that we have real tools. Evidence-based, well-tolerated tools that can meaningfully slow myopia progression in children. Here is what Dr. Clark and I both use, and what the research supports.

Low-dose atropine eye drops. This is the backbone of myopia management. Atropine has been used for this purpose for over a century — there are papers from the 1930s, controlled trials from the 1970s. The recent breakthrough was finding that very low concentrations (0.01% to 0.05%) produce meaningful slowing with minimal side effects. The right concentration is not one-size-fits-all. Dr. Clark starts most children at 0.01%, moves to 0.03% for higher-risk kids based on ethnicity, rate of progression, and family history, and reserves 0.05% for the most aggressive cases. One of the most important things he shared — and this matches what I have seen in practice — is that more is not always better. Some children paradoxically progress faster at higher concentrations. The CHAMP study showed that 0.03% performed worse than 0.01% in certain populations. You have to actually follow these kids and adjust.

MiSight contact lenses. These are soft daily disposable lenses designed to deliver peripheral defocus — correcting central and peripheral vision together, eliminating the signal that tells the eye to keep growing. Dr. Clark has fit children as young as five. He's found that young children often have better compliance than teenagers, because parents are doing the inserting and removing themselves, and the program includes a full lens supply so there's no incentive to overuse them. The data on contact lens complications with MiSight is actually lower than for standard contact lenses in older populations, for exactly these reasons. He's also found that adding MiSight to atropine in children who are poor atropine responders produces the most dramatic treatment effect of any combination he's used.

Peripheral defocus glasses. Same optical principle as MiSight, in spectacle form. Approved in Australia, Canada, Europe, Israel, and throughout Asia. Not yet FDA-approved for marketing in the United States, but — and this matters — optical devices don't require FDA approval to be sold, only to be marketed. They are available. No studies have shown adverse effects. The worst outcomes still outperform standard single-vision lenses by 30 to 50 percent. Dr. Clark offered a comparison I found cutting: the FDA's delay on beta blockers for heart attacks in the 1970s was later estimated to have caused over 100,000 excess deaths. He believes this will be viewed the same way eventually. I offer these lenses to families with full disclosure that they are not FDA-approved for marketing, and I have never had a parent who understood the situation choose not to use them.

What the "It Doesn't Work" Studies Actually Show

I want to spend a moment here because I know parents do their research, and there are studies out there — recent ones — claiming that low-dose atropine performs no better than placebo. Dr. Clark has done a deep dive into the data behind several of these, and what he found is important.

The problem is the placebo groups. Starting around 2019 and 2020, as awareness of myopia management grew, parents enrolled in studies became increasingly unwilling to let their child's vision worsen on a sugar-water control arm when they knew effective treatments existed. Children who were progressing rapidly on placebo were pulled out of studies. In one large Western study, 25 percent of the placebo group dropped out — and those who dropped out had progressed almost twice as fast as those who stayed. When you lose all the fast progressors from your control group, of course the treatment looks less impressive by comparison. In another study, a significant percentage of the placebo group showed paradoxical far-sighted changes in year two — because Asian families in the control group had quietly started orthokeratology on the side. Remove those confounders and the atropine data is virtually identical to every major Asian trial.

You cannot do a clean randomized controlled trial on a treatment when participants know whether it's working by watching their child's vision get worse. That is not a flaw in the medication. That is a flaw in the study design, and it reflects how much the field has changed.

How Long Do You Actually Treat?

The original studies looked at two years. I used to stop at two years. I don't anymore, and neither does Dr. Clark.

His analogy is the one I now use with every family: orthodontic retainers. You don't finish with braces and abandon all retention, because the underlying tendency for the teeth to shift doesn't disappear. The same is true for eyes. His practice data includes children who have been on low-dose atropine for fifteen years or more. Out of his entire dataset, fewer than ten stopped due to side effects.

He continues treatment until a patient is well past the rapid progression window — often into late adolescence, sometimes beyond. The goal is to protect as much of that childhood growth period as possible, because whatever they gain in eye size during those years, they carry for life.

What About Children Who Aren't Nearsighted Yet?

This is the conversation I find hardest to have, and the most important.

Dr. Clark said something that has stayed with me: myopia is like going down a hill. Once you are in motion, it takes much more effort to slow you down. If you can prevent the child from going down the hill at all — if you catch them at zero, at a quarter diopter, at the very edge — the outcomes are extraordinary. He has teenagers in his practice who have never needed glasses, who spend their days on devices, whose parents are high myopes, and they are holding steady. That is what early intervention can do.

The honest challenge is that this is a very difficult sell when a child sees perfectly. There is no felt urgency. And if the parents don't wear glasses, there is often genuine confusion about why you would treat something that doesn't appear to be a problem.

The answer is that the problem is happening right now, invisibly, in the growth patterns of that child's eye. Whatever they gain, they keep. The intervention that works at age seven doesn't work at age seventeen in the same way. And the vision loss that results from unchecked high myopia doesn't show up until adulthood — but by then, the structural damage is done and nothing can reverse it.

I treat my own children as pre-myopes. They don't love the drops. Honestly, I'm not sure they use them as consistently as I'd like. But I understand the research now in a way I didn't earlier in my career, and I am not willing to sit by when there is something I can do.

What I Want You to Take Into Your Next Eye Appointment

The biggest takeaway, in Dr. Clark's words: you can make a difference in your child's eyes.

You are not powerless. The prescription going up every year is not something you simply have to accept. But you may have to ask. Many eye doctors are still on the fence about myopia management, or don't bring it up unprompted. So be the one who brings it up.

Ask: my child's eyes keep getting worse — what can we do to slow that down?

If your child is already myopic, ask specifically about atropine. Ask about MiSight lenses. Ask about defocus glasses. Ask how aggressive the approach should be given your child's age, prescription, and risk factors.

If your child isn't myopic yet but has risk factors — two nearsighted parents, a lot of near work and indoor time, East Asian heritage, or a prescription that seems to be heading somewhere — ask what you're watching for and when intervention makes sense.

The last thing any of us wants is to sit in that exam room in ten years and realize there was a window, and it closed, and nobody said anything.

You can make a difference. But you have to be the one to ask.

Want to Learn More?

You can subscribe to my podcast, In Focus, anywhere you listen — or follow along on Instagram for updates and tips.

Watch this episode on YouTube right now!

Thanks for reading — and for doing what you can to protect your family's vision, one step at a time.

– Dr. Rupa Wong Pediatric Ophthalmologist | Surgeon | Mom of 3

This episode is brought to you by The Pinnacle Podcast Network! Learn more about Pinnacle at learnatpinnacle.com